Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

ABSTRACT:

Background

For people with HIV and CD4⁺ counts >500 cells/mm³, early initiation of antiretroviral therapy (ART) reduces serious AIDS and serious non-AIDS (SNA) risk compared with deferral of treatment until CD4⁺ counts are <350 cells/mm³. Whether excess risk of AIDS and SNA persists once ART is initiated for those who defer treatment is uncertain.

Methods

The Strategic Timing of AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults with CD4⁺ counts .500 cells/mm³ to immediate treatment initiation after random assignment (n = 2325) or deferred treatment (n= 2359). In 2015, a 57% lower risk of the primary end point (AIDS, SNA, or death) for the immed

SUBMITTER: Lundgren JD 

PROVIDER: S-EPMC10194271 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature